Nordion Reports Fourth Quarter and Fiscal 2012 Financial Results; Provides Fiscal 2013 Outlook

    Fourth quarter fiscal 2012 revenue of $74.7 million, up 1% from fiscal 2011; full year revenue of $244.8 million, down 11% from fiscal 2011
    TheraSphere® revenue for fourth quarter fiscal 2012 increased to $12.0 million, up 10% from fourth quarter fiscal 2011; full year TheraSphere revenue was up 14% from fiscal 2011
    Extended Mo-99 contract with Lantheus Medical Imaging for two additional years to 2015

Nordion reports in U.S. dollars unless otherwise specified

Nordion Inc. (NDN.TO) (NDZ), a leading provider of products and services to the global health science market, today reported results for the fiscal fourth quarter and year ended October 31, 2012. The Company generated $74.7 million in revenue for the fourth quarter fiscal 2012, an increase of $0.7 million, or 1%, over revenue of $74.0 million for the same period in fiscal 2011. Revenue for full year fiscal 2012 was $244.8 million, down 11% from revenue of $274.0 million in fiscal 2011.

Rosetta Genomics Reports Study Comparing microRNA Profiles of Cancer of Unknown Primary and Metastases of Known Primary Tumors Published in Clinical Experimental Metastasis

Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled "Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary (CUP) demonstrates no significant expression differences with metastases of matched known primary tumors."  The article can be viewed online at http://www.ncbi.nlm.nih.gov/pubmed/23124598.  

Response Biomedical Corp. Announces Expansion of U.S. Distribution for RAMP(R) Cardiovascular Products

Response Biomedical Corp. (RBM.TO)(RPBIF) today announced that it has entered into a distribution agreement with Laboratory Supply Company, Inc. (LABSCO), a leading distributor of innovative diagnostic technologies and laboratory products to hospitals, physician office laboratories and alternate healthcare settings with principal offices in Louisville, KY, USA to distribute its Cardiovascular portfolio of RAMP^® products in the U.S. exclusively to hospitals with less than 150 beds.

The U.S. Point of Care Testing (POCT) market is projected to be approximately $3.1B in 2013, representing the second largest In Vitro Diagnostic (IVD) category in the U.S. It is expected to continue to grow at 7.0% per year over the next several years¹.

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

First Automated Test Launches in Europe and Territories Recognizing the CE Mark

BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that the first automated version of the BGM Galectin-3^(R) blood test has obtained a CE Mark, an important step in the company's commercial strategy.

The BGM Galectin-3 test will be distributed through bioMerieux's VIDAS^(R) immunoassay platform which includes about 27,000 installed instruments worldwide.